Cream with cutaneous fibroblast lysate for the treatment of provoked vestibulodynia: A double-blind randomized placebo-controlled crossover study

Journal of Lower Genital Tract Disease

Volumn 16, Issue 4, 2012, Pages 427-436

  Donders, Gilbert G ^a,b   Bellen, Gert ^a  

^a Femicare vzw   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

cytokines; female sexual dysfunction; pain; vulvar vestibulitis; vulvodynia

Indexed keywords

PLACEBO; TOPICAL AGENT;

ABSENCE OF SIDE EFFECTS; ARTICLE; CELL LYSATE; CREAM; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DYSPAREUNIA; ERYTHEMA; FIBROBLAST; HUMAN; PAIN; SEXUAL BEHAVIOR; SEXUAL FUNCTION; SEXUAL INTERCOURSE; TREATMENT RESPONSE; VISUAL ANALOG SCALE; VULVODYNIA;

ADULT; CELL EXTRACTS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; FIBROBLASTS; HUMANS; MIDDLE AGED; PLACEBOS; VAGINAL CREAMS, FOAMS, AND JELLIES; VULVODYNIA; YOUNG ADULT;

EID: 84867575932     PISSN: 10892591     EISSN: 15260976     Source Type: Journal    
DOI: 10.1097/LGT.0b013e31825a2274     Document Type: Article

References (39)

1. Bergeron S, Binik YM, KhaliféS, Pagidas K, Glazer HI. Vulvar vestibulitis sYndrome: reliabilitY of diagnosis and evaluation of current diagnostic criteria. Obstet GYnecol 2001;98:45-51.
2. Meana M, Binik YM, Khalife S, Cohen DR. BiopsYchosocial profile of women with dYspareunia. Obstet GYnecol 1997;90:583-9.
3. Harlow BL, Wise LA, Stewart EG. Prevalence and predictors of chronic lower genital tract discomfort. Am J Obstet GYnecol 2001;185:545-50.
4. Burrows LJ, Klingman D, Pukall CF, Goldstein AT. Umbilical hYpersensitivitY in women with primarY vestibulodYnia. J Reprod Med 2008;53:413-6.
5. Bornstein J, Goldschmid N, Sabo E. HYperinnervation and mast cell activation maY be used as histopathologic diagnostic criteria for vulvar vestibulitis. GYnecol Obstet Invest 2004; 58:171-8.
6. Bornstein J, Cohen Y, Zarfati D, Sela S,Ophir E. Involvement of heparanase in the pathogenesis of localized vulvodYnia. Int J GYnecol Pathol 2008;27:136-41.
7. Foster DC, Piekarz KH, Murant TI, LaPoint R, Haidaris CG, Phipps RP. Enhanced sYnthesis of proinflammatorY cYtokines bY vulvar vestibular fibroblasts: implications for vulvar vestibulitis. Am J Obstet GYnecol 2007;196:346.e1-8.
8. Goldstein I. Hormonal factors in women's sexual pain disorders. In: Goldstein AT, Pukall CF, Goldstein I, eds. Female Sexual Pain DisordersVEvaluation and Management. Chichester, UK: Blackwell Publishing Ltd; 2009:180-94.
9. Johannesson U, Blomgren B, Hilliges M, RYlander E, Bohm-Starke N. The vulval vestibular mucosa-morphological effects of oral contraceptives and menstrual cYcle. Br J Dermatol 2007;157:487-93.
10. Goldstein A, Pukall CF. Provoked vestibulodYnia. In: Goldstein AT, Pukall CF, Goldstein I, eds. Female Sexual Pain DisordersVEvaluation and Management. Chichester, UK: Blackwell Publishing Ltd; 2009:43-8.
11. Friedrich EG. Vulvar vestibulitis sYndrome. J Reprod Medicine 1987;32:110-4.
12. Reissing ED, Brown C, Lord MJ, Binik YM, KhaliféS. Pelvic floor muscle functioning in women with vulvar vestibulitis sYndrome. J PsYchosom Obstet GYnaecol 2005;26:107-13.
13. LandrY T, Bergeron S, Dupuis MJ, Desrochers G. The treatment of provoked vestibulodYnia: a critical review. Clin J Pain 2008;24:155-71.
14. DanbY CS, Margesson LJ. Approach to the diagnosis and treatment of vulvar pain. Dermatol Ther 2010;23:485-504.
15. Bornstein J, Livnat G, Stolar Z, Abramovici H. Pure versus complicated vulvar vestibulitis: a randomized trial of fluconazole treatment. GYnecol Obstet Invest 2000;50:194-7.
16. NYirjesY P, Sobel JD,Weitz MV, Leaman DJ, Small MJ, Gelone SP. CromolYn cream for recalcitrant idiopathic vulvar vestibulitis: results of a placebo controlled study. Sex Transm Infect 2001;77:53-7.
17. Petersen CD, Giraldi A, Lundvall L, Kristensen E. Botulinum toxin tYpe AVa novel treatment for provoked vestibulodYnia? Results from a randomized, placebo controlled, double blinded study. J SexMed 2009;6:2523-37.
18. Foster DC, Kotok MB, Huang LS, Watts A, Oakes D, Howard FM, et al. Oral desipramine and topical lidocaine for vulvodYnia: a randomized controlled trial. Obstet GYnecol 2010;116:583-93.
19. Bornstein J, Tuma R, Farajun Y, Azran A, Zarfati D. Topical nifedipine for the treatment of localized provoked vulvodYnia: a placebo-controlled study. J Pain 2010;11:1403-9.
20. Gerber S, Applegate LA, Scaletta C, Burri N, Gremlich S, Hohlfeld P. Topical cYtokine creamfor vulvar vestibulitis. Poster presentation at VulvodYnia and Sexual Pain Disorders inWomen: A State of the Art Conference, Atlanta; October 2004.
21. Hohlfeld J, de BuYs Roessingh A, Hirt-Burri N, Chaubert P, Gerber S, Scaletta C, et al. Tissue engineered fetal skin constructs for paediatric burns. Lancet 2005;366:840-2.
22. Gold MH, Biron J. A novel skin cream containing a mixture of human growth factors and cYtokines for the treatment of adverse events associated with photodYnamic therapY. Drugs Dermatol 2006;5:796-68.
23. Gold MH, Goldman MP, Biron J. Human growth factor and cYtokine skin cream for facial skin rejuvenation as assessed bY 3D in vivo optical skin imaging. J Drugs Dermatol 2007;6:1018-23.
24. Hussain M, Phelps R, Goldberg DJ. Clinical, histologic, and ultrastructural changes after use of human growth factor and cYtokine skin cream for the treatment of skin rejuvenation. J Cosmet Laser Ther 2008;10:104-9.
25. Jones B, Kenward MG. Design and AnalYsis of Crossover Trials. London, UK: Chapman & Hall; 1989.
26. Senn S. Cross-over Trials in Clinical Research. 2nd ed. Chichester, UK: John WileY & Sons Ltd; 2002.
27. Haefner HK. Report of the International SocietY for the StudY of Vulvovaginal Disease terminologY and classification of vulvodYnia. J Low Genit Tract Dis 2007;11:48-9.
28. Farra JT, Young JP, LaMoureaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensitY measured on a 11-point numerical pain rating scale. Pain 2001; 94:149-58.
29. Donders G, Folens S, Peperstraete B, Bellen G. Age of sexual debut and central introital dYspareunia. Eur J Obstet GYnecol Reprod Biol 2011;158:90-2.
30. Donders G, Bellen G, Peperstraete B, Folens S. Simple surgical treatment for central introital dYspareunia. GYnecol Surg 2011. DOI: 10.1007/s10397-011- 0719-z
31. Werner S, Grose R. Regulation of wound healing bY growth factors and cYtokines. PhYsiol Rev 2003;83:835-70.
32. Braun S, Auf dem Keller U, Steiling H, Werner S. Fibroblast growth factors in epithelial repair and cYtoprotection. Philos Trans R Soc Lond B Biol Sci 2004;359:753-7.
33. Gerber S, Bongiovanni AM, Ledger WJ, Witkin SS. Defective regulation of the proinflammatorY immune response in women with vulvar vestibulitis sYndrome. Am J Obstet GYnecol 2002;186:696-700.
34. Jeremias J, Ledger WJ,Witkin SS. Interleukin 1 receptor antagonist gene polYmorphism in women with vulvar vestibulitis. Am J Obstet 2000;182:283-5.
35. Gerber S, Bongiovanni AM, Ledger WJ, Witkin SS. Interleukin- 1beta gene polYmorphism in women with vulvar vestibulitis sYndrome. Eur J Obstet GYnecol Reprod Biol 2003;107:74-7.
36. Pukall CF, PaYne KA, Binik YM, KhaliféS. Pain measurement in vulvodYnia. J Sex Marital Ther 2003;29(suppl 1): 111-20.
37. Pukall CF, Binik YM, KhaliféS, Amsel R, Abbott FV. Vestibular tactile and pain thresholds in women with vulvar vestibulitis sYndrome. Pain 2002;96:163-75.
38. Pukall CF, Young RA, Roberts MJ, Sutton KS, Smith KB. The vulvalgesiometer as a device to measure genital pressurepain threshold. PhYsiol Meas 2007;28:1543-50.
39. Foster DC, Kotok MB, Huang LS, Watts A, Oakes D, Howard FM, et al. The tampon test for vulvodYnia treatment outcomes research: reliabilitY, construct validitY, and responsiveness. Obstet GYnecol 2009;113:825-32.